CODX - Co-Diagnostics Corp Company Long-Term Debts

Graphic logo of CoDx (CODX)

Co-Diagnostics, Inc. (CODX) develops automated PCR testing systems that eliminate manual labor and enhance diagnostic accuracy. The business relies on stable demand for infection detection, providing resilience against economic downturns. The long-term liability ratio is 0.00. The asset's market dynamics reflect the growth of a company that has nearly reached the automation ceiling in DNA sequencing and biodata processing.

Co-Diagnostics, Inc. (CODX) - Company Long-Term Debts from 07/04/2022 to 10/29/2026

Co-Diagnostics Corp - analytical breakdowns and key metrics (CODX)

- share price and expert price forecast:
Share Price codiagnostics.com|CODX - Analyst Consensus Forecast
- market capitalization statistics:
Market Capitalization Co-Diagnostics|CODX - Total Company Value
- book value of equity indicators:
Equity per Share Co-Diagnostics|CODX - Book Capitalization|Market Capitalization to Book Value Ratio codiagnostics.com|CODX - Aggregate Company Assets
- debt level and financial liquidity data:
Debt to Equity Co-Diagnostics, Inc.|CODX - Long-Term Debt to Equity Ratio|Current Liabilities to Capital CoDx|CODX - Company Debts|Debts to Net Assets Co-Diagnostics|CODX - Company Long-Term Debts|Short-Term Debt Volume Co-Diagnostics|Interim Coverage Ratio codiagnostics.com
- earnings and valuation multiples indicators:
CODX - Net Profit
Analysis of all company metrics:CODX codiagnostics.com
Manufactured products of Co-Diagnostics

This indicator captures the total volume of liabilities with a maturity of more than one year, allowing for an assessment of the issuer's financial stability and the risk of frozen cash flows during downturns. By analyzing the company's long-term debt, an investor determines the balance between leverage and solvency. For Co-Diagnostics, Inc. (CODX), this metric reflects the cost of transforming the business toward the creation of a diagnostic IT platform amid falling demand for PCR tests.

Who Co-Diagnostics, Inc. competes with

A: Company Long-Term Indebtedness|Quest Diagnostics Incorporated - Company Long-Term Debts|ILMN - Company Long-Term Debts|Cologuard (EXAS) - Company Long-Term Debt|Company Long-Term Indebtedness RVTY|BIO (Bio-Rad Laboratories) - Company Long-Term Debts|Company Long-Term Debts anbio.com|Company Long-Term Debt Sotera Health (SHC)|Company Long-Term Debt QDEL (Quidel Corporation)|OPKO Corp - Company Long-Term Liabilities|CareDx (CDNA) - Long-Term Debt|MRVI - Company Long-Term Debt|Long-Term Debt Volume fulgentgenetics.com FLGT|LAB: Company Long-Term Debts|CTKB - Long-Term Debt Volume|Company Long-Term Debt OraSure Technologies Inc|Exagen Diagnostics (XGN) - Long-Term Debt Volume|Company Long-Term Debts MDXH|Company Long-Term Liabilities luciddx.com LUCD|Company Long-Term Debt Prenetics PRE|Insight Molecular Diagnostics, Inc. (IMDX) - Long-Term Debt|TRIB: Company Long-Term Liabilities|Long-Term Indebtedness ProPhase Labs Corp (PRPH)|AIMD: Company Long-Term Debts|Company Long-Term Indebtedness HSCS|BMRA (Biomerica) - Company Long-Term Debts|Cardio Diagnostics Holdings, Inc. (CDIO) - Long-Term Debt Volume|Company Long-Term Debts VRAX|Company Long-Term Debts Bluejay Diagnostics Corp (BJDX)|Company Long-Term Debts AWH (Aspira Women's Health)|Long-Term Indebtedness acceleratediagnostics.com|CNTG - Company Long-Term Debt|ENZ (Enzo Biochem, Inc.) - Company Long-Term Indebtedness|fresh2.co (FRES) - Company Long-Term Debt|Long-Term Debt Genetic Technologies Limited (GENE)|Company Long-Term Debt 23andMe Holding Co.|psychemedics.com (PMD) - Long-Term Debt Volume